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recall subjects. Most subjects were willing to pay extra to
have dental gel available, both for themselves and for
others, at amounts far exceeding the projected acquisi-
tion price.
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A WILLINGNESS-TO-PAY ASSESSMENT OF 
TWO TREATMENTS FOR OBESITY
Trakas K1,2, Oh PI1,2, Shear NH1,2
1University of Toronto, Toronto, ON, Canada; 2HOPE 
Research Centre, Sunnybrook and Women’s College Health 
Sciences Centre, Toronto, ON, Canada
Willingness-to-pay (WTP) provides a method of valuing
diverse outcomes of therapy in monetary units. The
methodology is based on informed individual’s willing-
ness to make trade-offs between health and a wide range
of commodities. OBJECTIVES: To determine the WTP
for weight-loss with two new weight reduction therapies,
orlistat (13.4 lbs) and sibutramine (12–14 lbs) in a Cana-
dian population. METHODS: WTP was assessed in 97
volunteers between the ages of 20 and 64 using contin-
gent valuation. Respondents were randomly assigned to
one of two bid strategies with randomly chosen starting
points. Demographic characteristics (i.e., age, sex, house-
hold income, education, smoking, height, weight, health-
related quality of life (EuroQol), and previous attempts
at weight-loss) were elicited using a standardized ques-
tionnaire. Main effects were tested by ANCOVA control-
ling for age, gender, education, income, smoking, and
obesity (Body Mass Index  30 kg/m2). RESULTS: Re-
spondents had a mean age of 34.6  10.6 years, were
predominantly female (64.6%), and had a mean EuroQol
score of 80.1  15.9 (out of 100). Only 22.7% of the re-
spondents were obese, however 61.9% reported having
tried to lose weight. Respondents stated that they would
be willing to pay an average of 13%  1.3% of their
monthly household income for orlistat and 11.1% 
1.3% for sibutramine (CDN$521 (95% CI: $450–$593)
vs. CDN$446 (95% CI: $375–$518) respectively; F 
0.0805, P  0.371) each month for a period of two years
(CDN$1  US$0.673). Estimates from respondents in
older age groups (P  0.001) and higher income levels (p 
0.001) were significantly associated with higher WTP
values. CONCLUSION: Individuals in Ontario, Canada
place a high value on pharmacologic therapies for weight
reduction.
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Diabetes is known to cause workforce exit after compli-
cations develop, yet little research has examined the ef-
fects of the disease and its treatment on work efficiency
while diabetics are employed. OBJECTIVE: The goal of
this research is to determine whether or not diabetes is
associated with lower levels of work productivity. METH-
ODS: To measure work productivity, a survey was de-
signed to collect data on work efficiency, as defined by
Osterhaus, et al. and van Roijen, et al. The survey also
included items about absences, work history, workforce
exit, job satisfaction, income, demographics and health
care utilization. The survey was administered to diabetic
and non-diabetic people who were employed. RESULTS:
On average, the 72 diabetics who completed the survey
reported significantly lower work productivity than their
362 non-diabetic co-workers. Diabetics averaged the
equivalent of seven hours of lost work time per month
while non-diabetics lost only four hours per month (P 
0.03). Surprisingly, the cost of these productivity losses
was not significantly different between diabetics and
non-diabetics. This is because the diabetics reported in-
comes that averaged $10,000 less per year than their
non-diabetic co-workers (P  0.02). CONCLUSIONS:
Diabetics appear to be less productive at work than their
non-diabetic peers, on average. The cost of lower produc-
tivity appears to be borne, at least in part, by the workers
themselves, who earn significantly less than their non-di-
abetic co-workers, on average. Given the rising preva-
lence of diabetes and variations in treatment patterns, the
effects of diabetes treatments on work productivity and
career progression deserves consideration.
PWP6
A PRELIMINARY STUDY OF PROVISION OF 
PHARMACEUTICAL CARE IN COMMUNITY 
PHARMACY IN SINGAPORE: COST ANALYSIS & 
PATIENT WILLINGNESS TO PAY
Li SC, Chan SY, How PPC
Department of Pharmacy, National University of Singapore, 
Crescent, Singapore
In Singapore, provision of pharmaceutical care by com-
munity pharmacists is not widely practiced. However,
two patient care centers were established in 1998 by a re-
tail pharmacy chain to provide a range of specialized
pharmaceutical care services. OBJECTIVES: This study
aimed to investigate the feasibility of having such services
in Singapore by (1) characterizing the customers utilizing
the pharmaceutical care services offered to identify a tar-
get group most likely to benefit from such services, and
(2) assessing customers’ perception and acceptance of the
services, as well as their willingness to pay for these ser-
vices. METHODS: A questionnaire was constructed to
evaluate the perception and acceptance of customers uti-
lizing the pharmaceutical care services. The questionnaire
was administered by a face-to-face interview. Qualitative
analysis of the responses was performed and where ap-
propriate, statistical analyses including ANOVA and un-
paired t-test were performed. RESULTS: Seventeen cus-
tomers completed the survey, representing 0.26% of the
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total number of customers who patronized the pharma-
cies during the study period. The mean respondents’ sat-
isfaction score was 4.24 (SD 0.52) out of a maximum
possible score of 5.0. Most respondents also supported
the suggestion of providing such services on a wider
scale. However, half the respondents indicated that they
were unwilling to pay for the professional services. CON-
CLUSION: The customers interviewed were satisfied
with the pharmaceutical care services provided but their
responses to paying for the services were less positive.
However, due to the limited time and small number of
participants in this project, a definite conclusion cannot
be drawn as to whether similar results would be obtained
if there were greater awareness by the public.
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INTRODUCTION: Sepsis is a pervasive problem world-
wide, and typically affects persons with significant under-
lying diseases, immunosupression, or major trauma. De-
spite recent advances in therapy and intensive care
medicine, mortality rates have remained essentially un-
changed over the past decade. Furthermore, sepsis is
poorly defined, usually incorporating septicemia, SIRS
and severe sepsis. OBJECTIVE: The purpose of this
study was to determine the outcomes and utilization of
hospital and ICU days in patients with severe sepsis.
METHODS: This evaluation was conducted as part of a
prospective, multi-center, cohort study (“Sepsis Longi-
tudinal Epidemiological Clinical Outcomes Tracking”
[SELECT] registry) in 398 patients with severe sepsis of
presumed infectious origin recruited through 45 ICU
units across the US. For each ICU admission, patient de-
mographic, ICU length of stay (LOS), hospital LOS and
hospital discharge status (dead or alive) was collected. In
addition, data concerning source of infection, comorbidi-
ties and treatments were also collected. RESULTS: In pa-
tients with severe sepsis, the most common comorbidities
were CVD (38%), respiratory failure (36%) and diabetes
(26%), and the majority were admitted from home
(73%). The most common sources of infection were pul-
monary (44%) and abdominal (23%). Overall mortality
in patients with severe sepsis was 42%. ICU survivors
had significantly longer mean hospital LOS (29 vs. 18
days, P  0.01) and ICU LOS (18 vs. 13 days, P  0.01)
compared to non-survivors. Both groups received similar
treatment. CONCLUSION: Based on these observations,
severe sepsis of presumed infectious origin is associated
with a high mortality rate and significant utilization of
hospital resources.
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THE BURDEN OF RESPIRATORY SYNCTIAL 
VIRUS (RSV) HOSPITALIZATIONS IN THE US
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OBJECTIVES: To quantify the burden to the US of RSV
associated hospitalizations using a new (October, 1996)
ICD-9 code for RSV bronchiolitis and two established
RSV codes. METHODS: We conducted a retrospective
analysis of two recent federal databases. The 1997 Na-
tional Hospital Discharge Survey (NHDS) was used to
identify the number of discharges among children under
age 5 with a primary diagnosis of RSV bronchiolitis
(ICD-9 466.11); RSV pneumonia (ICD 480.1) and RSV
(ICD-9 079.6); patient demographics; length of stay
(ALOS); and expected payment source. NHDS formulas
were used to estimate standard errors, normal distribu-
tions were assumed for the calculation of 95% CIs. Mean
charges were generated from the 1996 HCUP-3 NIS and
inflated to 1997 dollars using the Medical Care compo-
nent of the CPI (1.028). RESULTS: In 1997 an estimated
110,000 RSV-associated discharges occurred among chil-
dren under age five. RSV-bronchiolitis accounted for
84% [95% CI, 71%–97%] of RSV discharges; while
RSV pneumonia accounted for 15% [95% CI, 1%–
19%]. ALOS for RSV bronchiolitis was 3.5 days [95%
CI, 3.0–4.0]; 4.3 days [95% CI, 3.2–5.4] for RSV pneu-
monia; and 2.8 [95% CI, 0.3–5.2] for RSV. Mean hospi-
tal charges were $9572 for infants six months and
younger and $9056 for those under age one. 81%
[95%CI, 68%–94%] of children discharged with RSV
were under age one. CONCLUSIONS: Previous studies
may have underestimated the burden of RSV. Estimated
total 1997 hospital charges for RSV in children under age
5 were over $750 million with 75% ($580 million) for
RSV bronchiolitis. Medicaid insured 50% and private in-
surers covered 39% of these discharges. The actual burden
may be larger since RSV infections may be undercoded
and this analysis was restricted to primary diagnoses.
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Even though it is widely recognised that influenza is a se-
rious disease that causes significant consequences in
